Translational Research in Cancer

Croce, Carlo M.

Abstract

Thomas Jefferson University (TJU) has made cancer research one of its primary institutional priorities. The Jefferson Cancer Center (JCC) was established with the following mission: To increase the survival and quality of life of cancer patients by translating basic science discoveries into new strategies to diagnose, prevent and cure human cancer. To that end Dr. Carlo M. Croce, an expert in basic cancer research, was recruited as Director of the Jefferson Cancer Center in 1991 to establish first a strong research base for the Cancer Center. Subsequently major efforts were made to develop further the opportunities to forge a link between clinical programs and the basic science investigators. Dr. Robert L. Comis, who has substantial experience developing cancer related medical science programs, was recruited in 1993 to lead all of the clinically related patient care, teaching and research programs at Thomas Jefferson University. Working together, they have organized the scientific programs and administrative structure presented in this CCSG application. As Director, Dr. Croce has full authority for cancer related recruitment, space and resource allocation for the Jefferson Cancer Center, working in concert with the Dean, Dr. Comis and, where appropriate, other Department Chairpersons. The scientific program is divided into two interactive units: the Basic Science Division, under Dr. Croce's direction and the Medical Science Division, under Dr. Comis. The former includes five Established Programs: Cell Biology, Signal Transduction, Molecular Biology and Genetics, Structural Biology and Immunology; the latter includes: Developmental Therapeutics, Melanoma and Leukemia/Lymphoma, as well as two developing Programs: Prostate Cancer and Gastrointestinal Cancer. Thirteen shared resources support the scientific activity and two new clinically oriented resources support the resurgence in clinical trials research and human tissue procurement. All programs are focused on cancer, and interactions to maximize the synergy between scientific discovery and human oncology are abetted by this common interest and commitment of the leadership of the Jefferson Cancer Center and Thomas Jefferson University.

Funding Agency

• Agency: National Institute of Health (NIH)
• Institute: National Cancer Institute (NCI)
• Type: Center Core Grants (P30)
• Project #: 3P30CA056036-03S4
• Application #: 6156404
• Study Section: Cancer Center Support Review Committee (CCS)
• Program Officer: Shafik, Hasnaa
• Project Start: 1995-06-22
• Project End: 2001-05-31
• Budget Start: 1997-07-15
• Budget End: 2001-05-31
• Support Year: 3
• Fiscal Year: 1999

Institution

• Name: Thomas Jefferson University
• Department: Internal Medicine/Medicine
• Type: Schools of Medicine
• DUNS #: 061197161
• City: Philadelphia
• State: PA
• Country: United States
• Zip Code: 19107

Publications

Sullivan-Reed, Katherine; Bolton-Gillespie, Elisabeth; Dasgupta, Yashodhara et al. (2018) Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells. Cell Rep 23:3127-3136

Lu, Huimin; Bowler, Nicholas; Harshyne, Larry A et al. (2018) Exosomal ?v?6 integrin is required for monocyte M2 polarization in prostate cancer. Matrix Biol 70:20-35

Lapadula, Dominic; Farias, Eduardo; Randolph, Clinita E et al. (2018) Effects of Oncogenic G?q and G?11 Inhibition by FR900359 in Uveal Melanoma. Mol Cancer Res :

Vite, Alexia; Zhang, Caimei; Yi, Roslyn et al. (2018) ?-Catenin-dependent cytoskeletal tension controls Yap activity in the heart. Development 145:

McNair, Christopher; Xu, Kexin; Mandigo, Amy C et al. (2018) Differential impact of RB status on E2F1 reprogramming in human cancer. J Clin Invest 128:341-358

Garcia, Samantha A; Lebrun, Aurore; Kean, Rhonda B et al. (2018) Clearance of attenuated rabies virus from brain tissues is required for long-term protection against CNS challenge with a pathogenic variant. J Neurovirol 24:606-615

Vido, Michael J; Le, Kaitlyn; Hartsough, Edward J et al. (2018) BRAF Splice Variant Resistance to RAF Inhibitor Requires Enhanced MEK Association. Cell Rep 25:1501-1510.e3

Brody, Jonathan R; Dixon, Dan A (2018) Complex HuR function in pancreatic cancer cells. Wiley Interdiscip Rev RNA 9:e1469

Liao, Lili; Liu, Zongzhi Z; Langbein, Lauren et al. (2018) Multiple tumor suppressors regulate a HIF-dependent negative feedback loop via ISGF3 in human clear cell renal cancer. Elife 7:

Heeke, Arielle L; Pishvaian, Michael J; Lynce, Filipa et al. (2018) Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer Types. JCO Precis Oncol 2018: